Impavido for Dogs in the United States: Human FDA Label, Veterinary Use and the Miltefosine Evidence Boundary
Impavido is FDA-approved in the United States as a human prescription drug. Its label does not approve it for dogs. Veterinary sources describe miltefosine as a treatment for canine leishmaniosis, and VCA notes that the human product may be prescribed off-label in pets because the veterinary product Milteforan is difficult to obtain in North America.
"Approved" is often used to mean three different things:
-
Human FDA label: what the agency approved for people.
-
Veterinary evidence: what guidelines and studies say about dogs.
-
Extra-label use: a legal pathway that lets a veterinarian prescribe a human drug for an animal under federal conditions. It is not an approval.
Human approval, canine guidelines and extra-label authority answer separate questions, and none of them replaces the others.
Match each source to what it can prove
The Impavido label lists three indications. Visceral leishmaniasis due to Leishmania donovani, cutaneous leishmaniasis due to L. braziliensis, L. guyanensis and L. panamensis, and mucosal leishmaniasis due to L. braziliensis. Its limitations of use say geographic variation in response may exist and that efficacy in other Leishmania species has not been evaluated.
Canine disease in the WAVD guideline is caused by L. infantum, which is not among the species named in the human indications. That mismatch is one reason human label statements and human trial results should not be read as canine evidence. Any commercial listing that calls Impavido "FDA-approved" is referring to the human label.
The Milteforan record does not show a US approval, and none of the sources reviewed identified an FDA-approved veterinary miltefosine product. A product can be checked against Animal Drugs @ FDA using the application statement on its label.
What the canine evidence supports
The 2025 WAVD consensus statement was written by veterinary dermatology and parasitology specialists. It bases diagnosis on compatible clinical signs or laboratory abnormalities, exclusion of other diseases, demonstration of infection, and increased anti-Leishmania antibody concentration measured by quantitative serology. It advises avoiding drugs with anti-Leishmania activity in subclinically infected dogs.
For treatment, the abstract lists meglumine antimoniate with allopurinol and miltefosine with allopurinol as first-line options. It lists aminosidine with allopurinol as second-line. A separate conclusion in the paper states that miltefosine alone cannot be recommended because long-term efficacy data are limited and uncontrolled trials conflict.
The 2026 CLWG recommendations add a staging framework. They distinguish dogs that are seropositive but not infected, infected, sick and severely sick. They state that only sick dogs need anti-Leishmania treatment, and that confirming the parasite by direct tests, rather than serology alone, is strongly recommended before making treatment decisions. They also tell clinicians to consider the local epidemiology and the legal rules where they practice.
VCA's owner-facing page says miltefosine is often combined with allopurinol. It adds that miltefosine is unlikely to cure a dog but reduces clinical signs and infectivity.
Two limits apply to all of this.
-
Region and disease form matter. The CLWG focuses on Old World disease, and the WAVD document concerns L. infantum. A positive serology result in a dog that lives in or has traveled to a given region needs interpretation by the treating veterinarian.
-
Guidelines are not product approval. A guideline recommending a drug for dogs does not mean FDA has approved a particular product for them.
This article gives no canine dose, duration or regimen. Those belong to the prescribing veterinarian, and the human label's dosing should not be applied to a dog.
What lawful extra-label use requires
Extra-label use means using a drug in a way that differs from its approved labeling. FDA's Animal Medicinal Drug Use Clarification Act (AMDUCA) allows a veterinarian to consider extra-label use of certain approved human and animal drugs. This can occur only on the veterinarian's lawful order, within a valid veterinarian-client-patient relationship, and subject to federal conditions.
Impavido is an approved human drug, so that pathway is the relevant one for a US dog. AMDUCA describes who may decide and under what conditions. It does not tell you whether the drug is appropriate for your dog, and it does not make the human label a canine label.
Importing a veterinary product, or buying one from an online seller, raises separate legal and authenticity questions. A checkout page does not answer them.
Safety and handling context
The Impavido label carries a boxed warning for embryo-fetal toxicity. It states that the drug is contraindicated in pregnancy and advises effective contraception during treatment and for 5 months after the last dose for people able to become pregnant. It reports embryo-fetal toxicity in rats and rabbits, and follicular atresia with reversible anestrus or diestrus in dogs in nonclinical studies. These are human-label statements, and they are not a canine safety profile.
VCA's page describes miltefosine as a hazardous drug and gives several handling points:
-
People who are pregnant or nursing should not handle it.
-
Disposable gloves should be worn when handling the medication.
-
Gloves should also be worn when cleaning up if a dog vomits after a dose.
-
Treated dogs should not lick people right after the veterinary liquid form is given.
VCA lists pets that are pregnant, nursing or breeding among those that should not receive the drug. It also lists severe liver or kidney disease and cardiac disease as reasons for caution.
VCA names vomiting, diarrhea and loss of appetite as possible side effects. It advises baseline and periodic kidney and liver blood testing. It tells owners to stop the drug and contact the veterinarian immediately for signs it links to bone marrow suppression: fever, weakness, lethargy, pale gums and rapid breathing. These are secondary-source statements; follow the prescriber's instructions and contact the veterinarian or an emergency facility promptly if your dog develops these signs.
Questions for your veterinarian
Bring the product name, package or label photographs, and this list.
-
Diagnosis: How was leishmaniosis confirmed beyond a positive serology result? Which direct tests were used, and how do my dog's region and travel history affect their interpretation?
-
Disease stage: Is my dog considered infected, or sick? Does the stage change whether anti-Leishmania treatment is needed?
-
Treatment choice: Which option do current guidelines support for my dog, and why is miltefosine being considered? Will it be combined with another drug?
-
Exact product: Is the proposed product the human Impavido capsule, a veterinary solution such as Milteforan, or a compounded preparation? What are its formulation and strength, and who supplies it?
-
Legal basis: Is this extra-label use of an approved human drug under your order within a valid veterinarian-client-patient relationship?
-
Evidence boundary: Which parts of the plan come from canine guidelines, and which come from the human label or clinical experience?
-
Monitoring: Which tests will be done before and during treatment? Which signs mean I should stop the drug and call you?
-
Household handling: What precautions apply to anyone who is pregnant, nursing or planning a pregnancy? How do I handle vomit, saliva and leftover medication?
-
Reproductive status: Does my dog's pregnancy, nursing or breeding status change whether this medication is suitable?
The record to leave with: the human label shows what FDA approved for people, canine guidelines show what specialists recommend for dogs, and the prescribing veterinarian connects them for your dog under federal extra-label conditions.